| |
Renal Function in HCV Genotype 1-infected Treatment-naïve Patients Receiving Simeprevir in Combination with Peg-IFN and Ribavirin: A Post-hoc Analysis
|
| |
| |
Reported by Jules Levin
Presented at The Viral Hepatitis Congress Frankfurt, Germany 9-11 October 2014
Stefan Mauss,1 Maria Buti,2 Christophe Moreno,3 Graham R Foster,4 Ralph DeMasi,5 Alessandra Baldini,6 Michael Schlag,7 Guy De La Rosa,8 James Witek5
1Center for HIV and Hepatogastroenterology, DŸsseldorf, Germany; 2Liver Unit, Department of Internal Medicine, Hospital Valle d'Hebron and CIBERehd del Institut Carlos III, Barcelona, Spain;3Department of Gastroenterology and Hepatopancreatology, CUB H™pital Erasme , Universite Libre de Bruxelles, Brussels, Belgium; 4Queen Mary University of London, Liver Unit, London, UK;5Janssen Research & Development LLC, Titusville, NJ, USA; 6Janssen, Paris, France; 7Janssen Cilag, Vienna, Austria; 8Janssen Global Services,
from Jules: there appear to be concerns that kidney function could precipitously decline putting patients at significant health risk & for HCV treatability if patients are forced to delay HCV therapy unwarrantedly. The restriction imposed by Medicaid to only treat F3/F4 can put these patients at risk.
|
|
| |
| |
|
|
|
